Consun Pharma

Consun Pharma's reported carbon emissions

Consun Pharma, a pharmaceutical preparation manufacturer headquartered in China, has reported its greenhouse gas emissions for the years 2017 through 2022. In 2022, the company's total emissions, encompassing Scope 1 and Scope 2, were approximately 72,057,200 kg CO2e. This figure comprises about 53,214,680 kg CO2e from Scope 1 emissions, which include stationary combustion, mobile combustion, and fugitive emissions, and approximately 18,842,520 kg CO2e from Scope 2 emissions, primarily from purchased steam and electricity. In 2021, Consun Pharma's combined Scope 1 and 2 emissions stood at approximately 71,151,211 kg CO2e. This breaks down to about 52,549,121 kg CO2e for Scope 1, including stationary combustion, mobile combustion, and fugitive emissions, and approximately 18,602,090 kg CO2e for Scope 2, from purchased steam and electricity. Looking back, in 2020, the company reported total Scope 1 and 2 emissions of approximately 31,857,680 kg CO2e. Scope 1 emissions accounted for about 16,418,910 kg CO2e, with stationary combustion being the largest contributor, and Scope 2 emissions totalled approximately 15,438,760 kg CO2e, from purchased steam and electricity. In 2019, Consun Pharma's Scope 1 and 2 emissions were approximately 28,163,260 kg CO2e, with Scope 1 emissions at about 15,470,130 kg CO2e and Scope 2 emissions at approximately 12,693,130 kg CO2e. In 2017, total Scope 1 and 2 emissions were reported as approximately 21,049,000 kg CO2e, consisting of about 12,611,000 kg CO2e from Scope 1 (mobile and stationary combustion) and approximately 7,978,000 kg CO2e from Scope 2 (purchased electricity). Consun Pharma has not disclosed Scope 3 emissions data in the provided reports. Regarding climate commitments, while Consun Pharma's own reports do not detail specific reduction targets, the organisation "Asker" has stated a commitment to reducing its absolute Scope 1 and 2 emissions by at least 42% by 2030, using 2021 as a base year. It is important to note that this target is attributed to "Asker" and not explicitly stated as Consun Pharma's own. Consun Pharma's disclosures indicate a reliance on intensity metrics for carbon reporting, with greenhouse gas emission intensity per unit of revenue reported across various years. The company is currently not setting Science Based Targets.